NIPRO CORPORATION
8086・Prime Market・Precision Instruments
Medical-Related
Nipro's core segment. Deploys dialysis and injection/infusion-related medical devices both domestically and internationally, accounting for approximately 79% of consolidated net sales.
| Period | Current | Previous | Change |
|---|---|---|---|
| Net Sales (External Customers) | ¥523,615 million | ¥505,078 million | ↑ |
| Segment Profit (Operating Profit) | ¥52,338 million | ¥46,632 million | ↑ |
| Segment Assets | ¥779,012 million | ¥711,855 million | ↑ |
| Depreciation | ¥36,743 million | ¥34,789 million | ↑ |
| Increase in Tangible and Intangible Fixed Assets | ¥35,597 million | ¥41,493 million | ↓ |
| Goodwill Amortization | ¥2,004 million | ¥2,963 million | ↓ |
Business Details
The Domestic Division sells medical devices related to injection & infusion, artificial organs, high-function products, and dialysis, as well as pharmaceutical products related to diabetes, generics, and Kit Formulations. The International Division globally deploys medical devices related to injection & infusion, artificial organs, and diabetes through overseas manufacturing and sales sites. Aggressive overseas expansion—including a partnership with a major U.S. dialysis provider, winning bids under China's centralized procurement system, and strong performance of high-function dialyzers in Europe—is driving revenue.
Recent Overview
In FY2026 (ending March 2026), net sales increased 3.7% year-on-year and operating profit increased 12.2% year-on-year.
Net sales to external customers were ¥523,615 million (up 3.7% year-on-year), and segment profit was ¥52,338 million (up 12.2% year-on-year). Domestically, the lifting of hemodiafilter shipment restrictions and price optimization for injection needles and infusion products contributed. Overseas, expansion of the partnership with a major U.S. dialysis provider, a significant increase in dialyzer shipments under China's centralized procurement system, and strong sales of high-function dialyzers in Europe were the main drivers. Production capacity expansion progressed through the start-up of new lines at the Odate Plant (April and December 2025) and the completion of expansion/renovation of the Vietnam plant.
Key Products
Growth Drivers
- Expansion of dialyzer and dialysis-related product sales through a partnership with a major U.S. dialysis provider
- Significant increase in dialyzer shipment volumes from winning bids under China's centralized procurement system
- Production capacity expansion through the start-up of new lines at the Odate Plant (April and December 2025) and the completion of expansion/renovation of the Vietnam plant
- Strong sales of high-function dialyzers in Europe and expanding demand for dialysis equipment in Asia and Latin America
- Expanded deployment of Vascular-Related Products (intravascular imaging systems, balloon catheters) into Europe, the U.S., Asia, the Middle East, and Latin America
- Advancement of price optimization for domestic injection needles and infusion-related products, and the lifting of hemodiafilter shipment restrictions
Risks
- Pressure on profitability in the pharmaceutical sales division due to domestic drug price revisions and the selected medical care system
- Risk of rising manufacturing costs due to continued increases in raw material, labor, and transportation costs
- Intensifying price competition due to China's centralized procurement system and healthcare cost containment measures in various countries
- Impact on logistics and raw material procurement from geopolitical risks (Middle East situation, U.S.-China trade friction)
- Increased costs from expanding the sales structure amid overseas business expansion, and foreign exchange rate risk
Last updated: June 25, 2026